Moderna Could Have More than Seven Products on Market Next Year
Dow Jones
Aug 20
0900 GMT - Moderna's breakthrough on a vaccine for skin cancer puts the drug maker on course to have more than seven products on the market by 2027-28, Jefferies' Andrew Tsai writes. The company is diversifying its portfolio across respiratory and cancer treatments and AI-designed drugs, the analyst says. Revenues for 2026 could grow by up to 10% on 2025's $1.9 billion baseline, the analyst says, putting the company on track to break even in 2028. The trial success in Moderna's experimental mRNA-based cancer vaccine could help drive sales from 2027, Tsai says. Moderna shares fall back 12% premarket after the company more than doubled its market value Wednesday.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.